Correlation Between Inhibrx and Evoke Pharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Inhibrx and Evoke Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inhibrx and Evoke Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inhibrx and Evoke Pharma, you can compare the effects of market volatilities on Inhibrx and Evoke Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inhibrx with a short position of Evoke Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inhibrx and Evoke Pharma.

Diversification Opportunities for Inhibrx and Evoke Pharma

0.57
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Inhibrx and Evoke is 0.57. Overlapping area represents the amount of risk that can be diversified away by holding Inhibrx and Evoke Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Evoke Pharma and Inhibrx is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inhibrx are associated (or correlated) with Evoke Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Evoke Pharma has no effect on the direction of Inhibrx i.e., Inhibrx and Evoke Pharma go up and down completely randomly.

Pair Corralation between Inhibrx and Evoke Pharma

Given the investment horizon of 90 days Inhibrx is expected to generate 0.8 times more return on investment than Evoke Pharma. However, Inhibrx is 1.26 times less risky than Evoke Pharma. It trades about 0.0 of its potential returns per unit of risk. Evoke Pharma is currently generating about -0.06 per unit of risk. If you would invest  2,526  in Inhibrx on September 27, 2024 and sell it today you would lose (1,077) from holding Inhibrx or give up 42.64% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Inhibrx  vs.  Evoke Pharma

 Performance 
       Timeline  
Inhibrx 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Inhibrx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong fundamental drivers, Inhibrx is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors.
Evoke Pharma 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Evoke Pharma are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite quite inconsistent basic indicators, Evoke Pharma disclosed solid returns over the last few months and may actually be approaching a breakup point.

Inhibrx and Evoke Pharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Inhibrx and Evoke Pharma

The main advantage of trading using opposite Inhibrx and Evoke Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inhibrx position performs unexpectedly, Evoke Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evoke Pharma will offset losses from the drop in Evoke Pharma's long position.
The idea behind Inhibrx and Evoke Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

Other Complementary Tools

Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume